NTT/SAP
15.9.2016 11:13:23 CEST | Business Wire | Press release
SAP SE (NYSE:SAP) and Nippon Telegraph and Telephone Corporation (NTT) (NYSE:NTT) announced today its partnership enhancement in ‘Co-Innovation’, ‘Cross-Selling of Solutions’ and ‘Global Reference’.
SAP and NTT are collaborating by integrating cutting-edge technologies. As the first project of this initiative, to support safety operation of the transportation industry, the two companies have developed a solution combining SAP’s Connected Transportation Safety (CTS) solutions, which collects and analyzes vehicle related data, with NTT’s hitoe®, sensing fabric jointly developed with Toray Industries, and NTT IoT analytics platform, which provides driver’s biological data including heart rate and mental fatigue estimate, the project aims to provide more accurate and real-time information about vehicle and driver’s condition.
In cooperation with Keifuku Bus Co., Ltd (Fukui, Japan), SAP and NTT Group will conduct a field trial from October 2016, targeting to provide service from January 2017. The companies are planning to rollout this solution in the United States and Europe as well.
“We are honored to partner with NTT group who runs the world’s biggest data centers,” said Rob Enslin, member of the Executive Board of SAP SE and president of Global Customer Operations, SAP. “This partnership brings significant impact on SAP to broaden customers’ choice upon facilitating digital transformation. The integration of NTT’s cutting-edge technologies and SAP’s revolutionary solutions will generate momentum to elevate the overall market to the next level. By closely collaborating on a global scale, NTT and SAP will continuously strengthen ties to drive the three key initiatives including Co-innovation, Global Partnership, and SAP Solution Reference Customer in a long term perspective.”
“NTT aims to contribute to business transformation of its enterprise clients by providing high value-added services with partners.” said Jun Sawada, Senior Executive Vice President of NTT, “Global partnership with SAP is a significant step for strengthening our competitiveness in the rapidly changing ICT market. Through this partnership, along with SAP’s expertise and experiences, NTT can enhance its capabilities to support our global clients, and can accelerate digital transformation of industries.”
This co-innovation effort started in Palo Alto, California and has been led by NTT Labs and SAP Labs China. SAP and NTT Group intend to continue co-innovations in various areas with new technologies and expand its partnership through marketing promotion globally.
SAP and NTT Group have agreed to advance their digital practice collaboration and have formatted a new partner for Industrial Revolution. Primary target for 2016 is to move customers to the cloud for IoT and Industry 4.0.
While the partnership is not limited to Industrial Revolution, both companies are also accelerating their collaboration around private managed cloud solutions such as SAP HANA Enterprise Cloud leveraging NTT’s world class data center network around the globe. NTT is also a S/4 HANA Adoption Pinnacle Award Winner 2016.
In addition, NTT and SAP will create a global reference which could become a universal model. NTT has been working on establishing business platform as well as IT infrastructure to create synergy within the group. To accelerate the process, NTT is going to utilize the latest SAP solutions.
About SAP
As market leader in enterprise application software, SAP (NYSE: SAP) helps companies of all sizes and industries run better. From back office to boardroom, warehouse to storefront, desktop to mobile device – SAP empowers people and organizations to work together more efficiently and use business insight more effectively to stay ahead of the competition. SAP applications and services enable more than 320,000 customers to operate profitably, adapt continuously, and grow sustainably. The company is traded under the ‘SAP’ brand on the Frankfurt Stock Exchange, the New York Stock Exchange and other major global bourses. For more information, visit www.sap.com .
Copyright© 2016 SAP SE or an SAP affiliate company. All rights reserved.
SAP,
the SAP logo and other SAP products and services mentioned herein as
well as their respective logos are trademarks or registered trademarks
of SAP SE (or an SAP affiliate company) in Germany and other countries.
Other company names, logos, product names, etc. mentioned herein are the
registered trademarks or trademarks of the companies in question.
About Nippon Telegraph and Telephone Corporation (NTT)
NTT Group delivers advanced technology and innovative solutions in
networking, software communications, and cloud computing that help
transform businesses, governments and societies around the world.
NTT
Group will deliver convenient, enriched and reliable services to support
customers as a ‘Value Partner’ that its customers will continue to
select. Today, 85% of Fortune Global 100 companies rely on NTT Group as
their business partner. NTT Group generates over $95 billion in annual
revenues, has over 240 data centers and employs more than 241,000
professionals working in 87 countries. For more information, visit www.ntt-global.com
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160915005612/en/
Contact:
Media Contacts
SAP Global PR
contact
Jason Loesche
j.loesche@sap.com
or
SAP
Japan Co., Ltd.
Kaori Suzuki, +81-(3) 6737-3880 (division
switchboard); +81-80-1007-5933 (direct line)
Public Relations
kaori.suzuki@sap.com
or
Nippon
Telegraph and Telephone Corporation
Public Relations Office
ntt-cnr-ml@hco.ntt.co.jp
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
